All posts of Dr. Richard LeBlanc

Post-ASH 2018: MRD Evaluation of Patients with Multiple Myeloma Who Receive Bortezomib Consolidation after Frontline Tandem Transplantation

Poster presentation by Dr. Richard LeBlanc This phase II study evaluates the impact of bortezomib as a first-line treatment administered in consolidation after a tandem autologous transplant approach, followed by an allogeneic hematopoietic stem cell transplant in young or at-risk patients with multiple myeloma (MM). Previously published data (Ahmad I. et al., BMT 2016;51:529-535) demonstrate […]

Post-ASH 2018: The Tourmaline-MM3 Study Evaluating Ixazomib as Maintenance Therapy Following ASCT in the Treatment of Newly Diagnosed Myeloma

Oral presentation by Dr. Meletios A. Dimopoulos For patients with multiple myeloma being treated on a first-line basis and who have received an autologous hematopoietic stem cell transplant, the use of maintenance therapy has become a standard therapeutic approach. The phase III Tourmaline-MM3 study evaluates the impact of the first oral proteasome inhibitor, ixazomib, versus […]

L’étude Tourmaline-MM3 évaluant l’ixazomib en traitement d’entretien suite à une autogreffe de cellules souches dans le myélome nouvellement diagnostiqué

Présentation orale par le Dr Meletios A Dimopoulos Pour les patients atteints d’un myélome multiple en première ligne de traitement et qui ont reçu une autogreffe de cellules souches hématopoïétiques, l’utilisation d’un traitement d’entretien est devenue une approche thérapeutique standard. L’étude de phase III Tourmaline-MM3 évalue l’impact du premier inhibiteur des protéasomes oral, l’ixazomib, versus […]

Évaluation du bortezomib en consolidation suite à une approche tandem d’autogreffe suivie d’une allogreffe de cellules souches hématopoïétique

Présentation par affiche par le Dr Richard LeBlanc Cette étude de phase II évalue l’impact du bortezomib en première ligne de traitement administré en consolidation après une approche tandem d’autogreffe suivie d’une allogreffe de cellules souches hématopoïétique chez de jeunes patients ou ceux à mauvais risque atteints d’un myélome multiple. Les données publiées antérieurement (Ahmad […]

Late-Breaking Results from the Randomized, Phase III StaMINA Trial

The role of consolidation treatment after the first autologous stem cell transplantation (ASCT) remains a controversial issue and has been addressed in the BMT CTN 0702 trial presented by Dr. Edward Stadtmauer. This trial, also called StaMINA, is a phase III study for transplant-eligible patients with multiple myeloma in the first line. The trial enrolled […]

Results of the Phase III Myeloma XI Study Using Lenalidomide Maintenance

The U.K. XI trial is a phase III trial on a response-adapted approach to induction therapy in newly diagnosed patients with myeloma, transplant-eligible or not. Maintenance with lenalidomide reduced the risk of progression or death by 55%, with a median progression-free survival (PFS) of 37 months vs. 19 months in favour of maintenance. The improvement […]

Impressive Results from the POLLUX Trial

The addition of daratumumab to lenalidomide and dexamethasone (DRd) vs. lenalidomide and dexamethasone (Rd) alone was evaluated in the POLLUX trial, a randomized, open-label, multicentre, phase III study. The population of the study included 569 patients with multiple myeloma (MM), who had received at least one previous line of therapy. DRd treatment resulted in an […]

Thoughts on the Final Analysis of Overall Survival from the FIRST Trial

First-line treatment for newly diagnosed patients with multiple myeloma (MM), who are transplant-ineligible, is traditionally based on an alkylating agent (melphalan or cyclophosphamide) and/or a proteasome inhibitor (bortezomib). The pivotal FIRST trial compared MPT (melphalan, prednisone, and thalidomide) vs. Rd continuous (lenalidomide and dexamethasone until progression or unacceptable toxicity) vs. Rd18 (Rd for 18 cycles) […]